Abstract GS3-04: A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study)Heikki Joensuu, Henrik Lindman, Hans Wildiers et al.|Cancer Research|2018Cited by 12